View all AJHO CME

Share a PER® activity with your colleagues or friends. Connect with the PER® social network.



Accreditation/ Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 1.0 Contact Hour.

Acknowledgment of Commercial Support

This activity is funded by Physicians' Education Resource®, LLC.

Combination Therapy for Metastatic Melanoma



Release Date: January 21, 2016
Expiration Date: January 21, 2017
Media: Print with online posttest, evaluation, and request for credit

Overview

This activity is designed to inform physicians about the latest treatment advances in metastatic melanoma, including approved and investigational management strategies.

Instructions For This Activity & Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, "educational content/video" will be available for your reference.
  • In order to receive a CME/CE certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit.  Participants may immediately download a CME/CE certificate upon completion of these steps.

Target Audience

This activity is directed toward medical oncologists, primary care physicians, nurses, and nurse practitioners who treat patients with melanoma. Dermatologists, surgical oncologists, radiation oncologists, pathologists, fellows, physician assistants, and other healthcare providers interested in the management of melanoma are also invited to participate.

Learning Objectives

After participating in this CME activity, learners should be better prepared to:
  • Review FDA approvals for melanoma since 2011
  • Explain the mechanism by which combining a BRAF inhibitor with a MEK inhibitor increases responses/survival and decreases toxicities
  • Describe the differences in toxicities between vemurafenib and dabrafenib
  • Summarize pivotal data coming out of the CheckMate trials
  • Discuss the factors involved in the choice between monotherapy and combination therapy for first-line treatment of metastatic melanoma

The American Journal of Hematology/ Oncology® Editorial Board

Debu Tripathy, MD
Professor of Medicine and Chair
Department of Breast Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, TX
Disclosure: Grant/research support from Genentech/Roche, Pfizer, Puma Inc, and Novartis (clinical trial support contracted to the University of Southern California and MD Anderson Cancer Center); consultant for Eisai, Oncoplex Diagnostics, Merck, and Novartis.

Faculty

Antoni Ribas, MD, PhD
Professor of Medicine
Professor of Surgery Professor of Molecular and Medical Pharmacology Director
Tumor Immunology Program
David Geffen School of Medicine University of California
Jonsson Comprehensive Cancer Center
Los Angeles, CA
Disclosure: Amgen Inc; Genentech; GlaxoSmithKline; Merck & Co, Inc; Roche; stock/Shareholder: Kite Pharma, Inc; Compugen; CytomX.

Staff/Planner Disclosures and Conflict of Interest Resolution

The staff of Physicians' Education Resource®, LLC, (PER®) and the editorial staff of The American Journal of Hematology/Oncology® have no relevant financial relationships with commercial interests to disclose.

In accordance with Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial SupportSM, PER® resolved all conflicts of interest prior to the release of this CME activity using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for CME purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient's medical condition.

Disclaimer

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

Hardware And Software Requirements

Supported Browsers
Internet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)

Minimum System Requirements (Windows)
  • A Pentium-based PC or compatible computer
  • At least 64MB of RAM
  • Windows 95/98/NT/ME/2000/XP/Vista system software
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise
Minimum System Requirements (Mac OS)
  • A PowerPC processor-based Macintosh computer
  • At least 64MB of RAM
  • Mac OS 7.5 or later
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise
     




Calendar of Events
SUNMONTUESWEDTHURSFRISAT
   1234
567891011
12131415161718
19202122232425
262728293031
Filter By